In The News
Hypoglycemia in Type 1 Diabetes: Near term challenges, long-term risks, and the need for new therapeutics options
Carmen Valcarce, Executive Vice President and Chief Scientific Officer of vTv Therapeutics discusses the complex issues surrounding the treatment of type 1 diabetes, looking in particular at hypoglycemia and the impact it has both on patients and researchers.
This article is taken from Pharmafile Spring 2021, pages 39-41 © Samedan Ltd
Realize the Potential of Adjunctive Therapy in the Treatment of Type 1 Diabetes
One approach to improve care and clinical outcomes for people with type 1 diabetes involves the use of adjunctive therapies along with insulin to improve glucose control or enable reductions in insulin doses.